What changed
$NTRA — BUY 📊
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
🎯 Q2 2026 | Rev $1B | EPS $-0.60 vs $-0.55 🔴
💡 Consensus fixates on the EPS miss and near-term profitability, but underestimates (1) Signatera's expanding clinical evidence and guideline inclusion, (2) operating leverage from a scalable platform, and (3) the transplant rejection testing opportunity. Revenue growth will re-accelerate, and losses will narrow faster than modeled.
📉 Reward/Risk: 2.47:1
🏢 Business Quality: 8/10 - Strong IP portfolio, sticky recurring revenue from monitoring tests, large TAM in oncology and transplant, high switching costs from clinical integration, but unprofitable and faces competition.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/NTRA0623
Why it matters
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.